



ROSCOE

Actual ELIAS Patient.  
Read his story [here](#).

## Cancer Immunotherapy. Realized.

Now, the potential of harnessing a dog's own immune system to successfully treat cancer is becoming a reality.

ELIAS Cancer Immunotherapy (ECI<sup>®</sup>), an autologous prescription product, is the only combination adoptive cell therapy treatment available in veterinary medicine. It brings together the power of a personalized cancer vaccination with activated “killer” T cell therapy. The possibility of improved survival rates, prolonged life and better quality of life is showing up in the data. ECI is available commercially under 9 CFR 103.3 as an experimental product in select veterinary hospitals nationwide.

### Clinical Trials. Now Enrolling.

ELIAS is currently conducting a follow-up study to pursue licensure of ECI. This fully-funded clinical trial will enroll dogs that have been diagnosed with osteosarcoma but have not yet been treated for their cancer. It will be a two-arm study with a 1:1 randomization comparing ECI and carboplatin.

Learn more at [ELIASAnimalHealth.com/ECI-OSA-04](https://ELIASAnimalHealth.com/ECI-OSA-04)

